SuperworthEloxx Pharmaceuticals EPS ELOX
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$0.66
- Fiscal year 2023
- −$77.77
Eloxx Pharmaceuticals' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$0.66.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2023 | −$77.77 | n/a |
| FY2022 | −$183.15 | n/a |
| FY2021 | −$444.40 | n/a |
| FY2020 | −$378.40 | n/a |
| FY2019 | −$589.60 | n/a |
| FY2018 | −$638.00 | n/a |
| FY2017 | −$1570.80 | n/a |
| FY2017 | −$1927.20 | n/a |
| FY2016 | −$3696.00 | n/a |
| FY2015 | −$11968.00 | n/a |
| FY2014 | −$23320.00 | n/a |
| FY2013 | −$47784.00 | n/a |
| FY2012 | −$70400.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.66 | n/a | n/a | |
| Q1 FY26 | −$0.88 | n/a | n/a | |
| Q2 FY25 | −$5.45 | n/a | n/a | |
| Q1 FY25 | −$4.95 | n/a | n/a | |
| Q4 FY23 | −$10.12 | n/a | −$77.77 | |
| Q3 FY23 | −$14.41 | n/a | −$99.77 | |
| Q2 FY23 | −$21.56 | n/a | −$123.53 | |
| Q1 FY23 | −$31.68 | n/a | −$155.87 | |
| Q4 FY22 | −$32.12 | n/a | −$183.15 | |
| Q3 FY22 | −$38.17 | n/a | −$212.63 | |
| Q2 FY22 | −$53.90 | n/a | −$222.86 | |
| Q1 FY22 | −$58.96 | n/a | −$406.56 |
Against its peers
Companies in Healthcare nearest Eloxx Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ELOXEloxx Pharmaceuticals | n/m | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| SPROSpero Therapeutics | $0.11 | |
| NEPHNephros | $0.16 | +33% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Eloxx Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.